eCite Digital Repository

Pharmacological priming of adipose-derived stem cells for paracrine VEGF production with deferoxamine

Citation

Liu, GS and Peshavariya, HM and Higuchi, M and Chan, EC and Dusting, GJ and Jiang, F, Pharmacological priming of adipose-derived stem cells for paracrine VEGF production with deferoxamine, Journal of Tissue Engineering and Regenerative Medicine, 10, (3) pp. E167-E176. ISSN 1932-6254 (2016) [Refereed Article]

Copyright Statement

Copyright 2013 John Wiley & Sons, Ltd.

DOI: doi:10.1002/term.1796

Abstract

Adipose-derived stem cells (ASCs) show great potentials in applications such as therapeutic angiogenesis, regenerative medicine and tissue engineering. Pharmacological preconditioning of stem cells to boost the release of cytoprotective factors may represent an effective way to enhance their therapeutic efficacy. In this study, the aim was to determine whether deferoxamine can enhance the release of vascular endothelial growth factor (VEGF) from in vitro expanded ASCs. It is demonstrated that deferoxamine (50-300 μm) upregulated VEGF expression in a concentration- and time-dependent fashion. At the concentrations used, deferoxamine did not show any cytotoxic effects. The stimulatory effect of deferoxamine on VEGF expression was mediated by augmentation of hypoxia inducible factor-1 in ASCs, but independent of its antioxidant properties. Moreover, deferoxamine enhanced the paracrine effects of ASCs in promoting the regenerative functions of endothelial cells (migration and in vitro wound healing activities). This study provides evidence that deferoxamine might be a useful drug with low cell toxicity for pharmacological preconditioning of ASCs to enhance their capacity of VEGF production.

Item Details

Item Type:Refereed Article
Keywords:adipose-derived stem cells, deferoxamine, hypoxia inducible factor-1, paracrine, pharmacological preconditioning, vascular endothelial growth factor
Research Division:Technology
Research Group:Medical Biotechnology
Research Field:Gene and Molecular Therapy
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Inherited Diseases (incl. Gene Therapy)
Author:Liu, GS (Dr Guei-Sheung Liu)
ID Code:120694
Year Published:2016
Web of Science® Times Cited:8
Deposited By:Menzies Institute for Medical Research
Deposited On:2017-08-30
Last Modified:2017-11-03
Downloads:0

Repository Staff Only: item control page